Preclinical studies have demonstrated the neuroprotective effects of gypenosides in neurological disorders such as depression, PD, and AD by modulating important signaling pathways, including NF-κB, AKT, and ERK1/2, through activation of the Nrf2/KEAP1/ARE/HO-1 pathway [116]. Here, NFE2L2 is linked to Parkinson disease.